Emplicure AB changes the Q2 reporting date to August 29

The Board of Directors of Emplicure AB has decided to change the date of the company's Q2 report to August 29 (previously August 23).

For additional information, please contact

Håkan Engqvist

CEO
Phone: +46 702 569 500
Email: [email protected]

Erik Magnusson

CFO
Phone: +46 708 565 245
Email: [email protected]

Certified Adviser

Emplicure AB (publ) is listed on the Nasdaq First North Growth Market. Certified Adviser is Erik Penser Bank.

Emplicure develops new and innovative products by combining existing and approved active substances with advanced materials science within ceramic biomaterials. The product portfolio is focused on chronic pain and on abuse-deterrent formulations. The subsidiary Amplicon AB develops consumer products with oral nicotine as the first product. The share is listed on Nasdaq First North Growth Market (EMPLI). Read more at www.emplicure.com


Om Emplicure

Emplicure utvecklar nya innovativa produkter baserat på kombinationen av redan godkända aktiva substanser och avancerad materialvetenskap inom biokeramer. 

Webbplats
www.emplicure.com
Bransch
Sjukvård

Prenumerera

Få löpande information från Emplicure via e-post.

Handelsinformation

Kurs ()
Förändring ()
Marknad Nasdaq First North Growth Market Kortnamn EMPLI ISIN-kod SE0015812391 Certified Adviser Erik Penser Bank

IR-Kontakt

Håkan Engqvist VD [email protected]